Dialysis News and Research RSS Feed - Dialysis News and Research

When your kidneys are healthy, they clean your blood. They also make hormones that keep your bones strong and your blood healthy. When your kidneys fail, you need treatment to replace the work your kidneys used to do. Unless you have a kidney transplant, you will need a treatment called dialysis.

There are two main types of dialysis: hemodialysis and peritoneal dialysis. Both types filter your blood to rid your body of harmful wastes, extra salt and water. Hemodialysis does that with a machine. Peritoneal dialysis uses the lining of your abdomen, called the peritoneal membrane, to filter your blood. Each type has both risks and benefits. They also require that you follow a special diet. Your doctor can help you decide the best type of dialysis for you.
Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis. [More]
U.S. Renal Care, DSI Renal sign definitive merger agreement

U.S. Renal Care, DSI Renal sign definitive merger agreement

U.S. Renal Care, Inc. and DSI Renal announced Monday they have entered into a definitive merger agreement. USRC is the third largest dialysis provider in the country, and when combined with DSI, the company will serve approximately 23,000 patients across 33 states and the Territory of Guam. [More]
WHO provides emergency health access to internally displaced persons, host communities in Taiz and Hodeida governorates

WHO provides emergency health access to internally displaced persons, host communities in Taiz and Hodeida governorates

In response to the growing humanitarian crisis in Tiaz and Hodeida governorates, and the rising number of civilian injuries in the southern governorates of Yemen, WHO is coordinating a rapid response to provide emergency health access to the injured, internally displaced persons and host communities. [More]
Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Wyss Institute scientists develop improved blood-cleansing therapeutic device to treat sepsis

Last year, a Wyss Institute team of scientists described the development of a new device to treat sepsis that works by mimicking our spleen. It cleanses pathogens and toxins from blood circulating through a dialysis-like circuit. Now, the Wyss Institute team has developed an improved device that synergizes with conventional antibiotic therapies and that has been streamlined to better position it for near-term translation to the clinic. [More]
EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
DaVita HealthCare Partners hosts health and disaster preparedness fair in Colorado Springs

DaVita HealthCare Partners hosts health and disaster preparedness fair in Colorado Springs

DaVita HealthCare Partners Inc., one of the nation's largest and most innovative health care communities, is hosting a health and disaster preparedness fair on Saturday, Aug. 22, at the St. Francis Medical Center off Woodmen Road in Colorado Springs. [More]
Quanta receives i4i award from NIHR to develop new product concept for nocturnal haemodialysis

Quanta receives i4i award from NIHR to develop new product concept for nocturnal haemodialysis

Quanta Fluid Solutions Ltd, a pioneering developer of advanced haemodialysis systems, announces it has received an Invention for Innovation (i4i) award worth £1.85 million from the National Institute for Health Research - the research arm of the NHS - to develop a new product concept for nocturnal haemodialysis. [More]

NxStage System One now used in eight of Top 10 Nephrology Hospitals in the U.S.

NxStage Medical, Inc., a leading manufacturer of dialysis products, today announced that the NxStage System One is now used in eight of the Top 10 Nephrology Hospitals in the United States as ranked according to U.S. News & World Report. [More]
Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx reports net income of $9.0 million for second quarter 2015

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015. [More]
Only 1 in 4 patients with ESRD in Georgia referred for kidney transplant evaluation

Only 1 in 4 patients with ESRD in Georgia referred for kidney transplant evaluation

Only about one in four patients with end-stage renal disease in Georgia were referred for kidney transplant evaluation within 1 year of starting dialysis between 2005 and 2011, although there was substantial variability in referral among dialysis facilities, according to a study in the August 11 issue of JAMA. [More]
LA BioMed researcher launches study to examine medication adherence among patients with dialysis

LA BioMed researcher launches study to examine medication adherence among patients with dialysis

Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated. [More]
Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015. [More]
UChicago Medicine contributes to Illinois Transplant Fund

UChicago Medicine contributes to Illinois Transplant Fund

The University of Chicago Medicine has become the first transplant center to contribute to the Illinois Transplant Fund (ITF), a new not-for-profit that provides financial support for organ transplants to qualified uninsured residents of northern and central Illinois and Northwest Indiana. [More]
Finding by UCSF researchers could increase availability of kidneys for transplant

Finding by UCSF researchers could increase availability of kidneys for transplant

Mild hypothermia in deceased organ donors significantly reduces delayed graft function in kidney transplant recipients when compared to normal body temperature, according to UC San Francisco researchers and collaborators, a finding that could lead to an increase in the availability of kidneys for transplant. [More]
NEJM suggests use of HCV-positive kidneys as one solution to kidney shortage

NEJM suggests use of HCV-positive kidneys as one solution to kidney shortage

The average wait time for a kidney transplant is five years and there are more than 100,000 people on the waiting list. However, there are thousands of viable hepatitis C-positive kidneys that are discarded each year solely because they're infected. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
UC San Diego researchers identify pivotal player in diabetic kidney disease

UC San Diego researchers identify pivotal player in diabetic kidney disease

Tapping the potential of metabolomics, an emerging field focused on the chemical processes of metabolism, researchers at University of California, San Diego School of Medicine have identified a new and pivotal player in diabetic kidney disease. [More]
Tyrone Regional Health Network signs letter of intent to become member of Penn State Health

Tyrone Regional Health Network signs letter of intent to become member of Penn State Health

Tyrone Regional Health Network and Penn State Health have signed a letter of intent to enter into formal affiliation. With approval by organizational boards and state authorities, Tyrone Regional will become a member of Penn State Health. [More]
New drug patiromer could improve potassium levels of patients with diabetic kidney disease

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA. [More]
Advertisement